Keytruda and Cellulitis - a phase IV clinical study of FDA data

Summary:

Cellulitis is reported as a side effect among people who take Keytruda (pembrolizumab), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Lenvima, and have Endometrial cancer.

The phase IV clinical study analyzes which people have Cellulitis when taking Keytruda. It is created by eHealthMe based on reports of 57,304 people who have side effects when taking Keytruda from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Cellulitis?

Cellulitis (infection under the skin) is found to be associated with 2,081 drugs and 2,340 conditions by eHealthMe. Check the latest studies of Cellulitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 20, 2026

57,304 people reported to have side effects when taking Keytruda.
Among them, 111 people (0.19%) have Cellulitis.

Among these 111 people:

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and have Cellulitis?

- Check whether Cellulitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keytruda:

Keytruda (57,404 reports)

Cellulitis treatments and more:

Cellulitis (75,291 reports)

How severe was Cellulitis and when was it recovered:

Cellulitis in Keytruda

Expand to all the drugs that have ingredients of pembrolizumab:

Cellulitis and drugs with ingredients of pembrolizumab (225 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Keytruda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cellulitis:

Cellulitis (2,081 drugs)

Browse all the conditions that are associated with Cellulitis:

Cellulitis (2,340 conditions)

Related publications that referenced our studies

Yaylaci S, Yilmaz EU, Guclu E, Kumsar NA, Tamer A, Karabay O, "Clozapine-Induced Febrile Neutropenia and Cellulitis", Turkish journal of emergency medicine, 2014 Mar .
Yaylaci S, Yilmaz EU, Guclu E, Kumsar NA, Tamer A, Karabay O, "Clozapine-Induced Febrile Neutropenia and Cellulitis", Turkish journal of emergency medicine, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on pembrolizumab (the active ingredients of Keytruda) and Keytruda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.